Continuous low-irradiance photodynamic therapy: a new therapeutic paradigm.
A principal factor in determining the biologic consequences of photodynamic therapy (PDT) is the light fluence rate. Preclinical and, more recently, clinical studies have focused on low-irradiance schemes, suggesting that prolonged light exposure, better known as CLIPT (continuous low-irradiance PDT), may improve tumor control while reducing morbidity. After a brief look at the origin of light therapy and photosensitizers, this article turns to the promising animal research supporting the use of low- and ultra-low fluence rate PDT, which serves as the basis of the ongoing CLIPT dosimetry trials for patients with chest wall progression of breast cancer. The future of CLIPT seems to be a home-based therapy using a portable, self-contained energy delivery system.
Dermatologic Surgery & Oncology, Tufts University School of Medicine, Tufts Medical Center, Boston, MA, USA. grogers@tuftsmedicalcenter.org
Gary S
GS
Rogers
D000622:Aminolevulinic Acid / Q000627:therapeutic use; D000818:Animals; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017323:Dihematoporphyrin Ether / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006801:Humans; D008027:Light; D008652:Mesoporphyrins / Q000627:therapeutic use; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*
D008652:Mesoporphyrins; D017319:Photosensitizing Agents; D000622:Aminolevulinic Acid; D017323:Dihematoporphyrin Ether; C072269:temoporfin